FAKTOR-OPTIONSSCHEIN - INCYTE CO. Stock

DE000SD416S6

Market Closed - Bid/Ask 02:03:40 2024-05-23 pm EDT			After market 02:33:28 pm
2.43 ^EUR	+2.53%		2.445	+0.62%

Current month	-52.51%
1 month	-51.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	12:47pm	MT
Incyte Acquires 2 Office Buildings in Delaware	May. 21	MT
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings	May. 21	BU
Incyte to Present at Upcoming Investor Conference	May. 21	BU

More news

Quotes 5-day view

Date	Price	Change
24-05-23	2.43	+2.53%
24-05-22	2.37	-5.58%
24-05-21	2.51	-3.09%
24-05-20	2.59	+1.17%
24-05-17	2.56	-2.66%

Real-time Boerse Frankfurt Warrants

Last update May 23, 2024 at 02:03 pm EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Société Générale
WKN	SD416S
ISIN	DE000SD416S6
Date issued	2021-03-29
Strike	79.94 $
Maturity	Unlimited
Parity	1 : 1
Emission price	8.47 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	17.82 €
Lowest since issue	0.91 €
Spread	0.01 €
Spread %	0.41%

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

58.2 USD

Average target price

72.8 USD

Spread / Average Target

+25.09%

Consensus